London, United Kingdom, January 21, 2026 — GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, securing global rights to the experimental food allergy therapy ozureprubart, excluding select Asian markets. The deal marks GSK’s first major acquisition under newly appointed CEO Luke Miels and signals a strategic move to strengthen the company’s pipeline as it prepares for upcoming patent expirations in its HIV franchise.
Science Significance
From a scientific perspective, the acquisition centers on ozureprubart, a lab-engineered immunotherapy designed to target an antibody that drives allergic inflammation. By intervening upstream in the immune cascade responsible for food allergy reactions, the therapy aims to reduce hypersensitivity responses to common allergens such as peanuts, milk, eggs, and tree nuts. Notably, ozureprubart is being evaluated with 12-week dosing intervals, potentially offering a less frequent and more convenient treatment option compared to existing therapies. The approach reflects growing scientific interest in long-acting immune-modulating biologics that can improve disease control while minimizing treatment burden.
Regulatory Significance
Regulatory considerations are central to the value of the transaction. Ozureprubart is currently in a mid-stage clinical trial involving patients aged 12 to 55, with data expected in 2027. The study is designed to assess whether patients can tolerate higher allergen exposure without triggering reactions, a clinically meaningful endpoint for regulators evaluating efficacy in food allergy indications. By acquiring the asset at this stage, GSK gains the opportunity to shape late-stage development, regulatory strategy, and global submission pathways, leveraging its extensive experience in navigating complex biologics approvals across major markets.
Business Significance
Advertisement
Strategically, the deal underscores GSK’s focus on “bolt-on” acquisitions that address validated targets and clear unmet medical needs. The company has agreed to pay $58 per share, representing a 65% premium over RAPT’s prior closing price, reflecting confidence in the asset’s long-term potential. The acquisition also aligns with GSK’s broader effort to diversify revenue streams as patents for its top-selling HIV drug approach expiry in 2028. Analysts note that while ozureprubart is earlier-stage than some investors expected, it fits GSK’s stated strategy of building a portfolio of differentiated, long-acting medicines to support sustainable growth toward its 2031 revenue targets.
Patients’ Significance
For patients and families affected by food allergies, the deal highlights progress toward new therapeutic options in a relatively underserved market. Food allergies often require strict dietary avoidance and carry the risk of life-threatening anaphylaxis, particularly in pediatric populations. A therapy that can increase allergen tolerance with infrequent dosing could significantly improve quality of life, reduce anxiety, and enhance long-term adherence. If successful, ozureprubart may offer an alternative to existing biologics that require more frequent administration, supporting broader acceptance among patients and caregivers.
Policy Significance
At a policy level, the acquisition reflects renewed momentum in pharmaceutical mergers and acquisitions as large companies seek to replenish pipelines ahead of major patent cliffs. The transaction also illustrates how innovation in immunology and allergy is becoming a priority area alongside oncology and rare diseases. Policymakers and health systems are increasingly focused on therapies that address chronic conditions with high societal burden, particularly those affecting children. Investment in food allergy treatments aligns with public health goals to reduce emergency care utilization and improve long-term disease management.
Overall, GSK’s $2.2 billion acquisition of RAPT Therapeutics represents a strategic M&A move that combines scientific promise with long-term portfolio planning. By securing ozureprubart, GSK strengthens its position in immunology and allergy, while demonstrating a disciplined approach to dealmaking under new leadership. For the cGxP.wire audience, the transaction highlights how targeted acquisitions, regulatory foresight, and patient-centered innovation are shaping the next phase of growth for global pharmaceutical companies.
Source: GSK press release
